Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira® biosimilar)
June 16, 2016 08:00 ET
|
Oncobiologics, Inc.
CRANBURY, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing...
Oncobiologics Announces Separation of Units; Trading of Common Stock and Warrants
June 10, 2016 16:30 ET
|
Oncobiologics, Inc.
CRANBURY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing...
Oncobiologics Announces Closing of Initial Public Offering of Units
May 18, 2016 10:35 ET
|
Outlook Therapeutics, Inc.
CRANBURY, N.J., May 18, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing...